Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma 4Stomach Neoplasms 3Ovarian Neoplasms 3Carcinoma, Ovarian Epithelial 3Urinary Bladder Neoplasms 2Neoplasms 2Fallopian Tube Neoplasms 2Peritoneal Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Glandular and Epithelial 1EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) 1Ascites 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × catumaxomab × Clear all
NCT04222114 2023-01-31

Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis

LintonPharm Co.,Ltd.

Phase 3 Unknown
282 enrolled
Gastrointestinal

Stomach Neoplasms

NCT00464893 2013-12-04

Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection

Neovii Biotech

Phase 2 Completed
70 enrolled
Gastrointestinal

Stomach Neoplasms

NCT00352833 2007-10-26

Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma

Neovii Biotech

Phase 2 Completed
40 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡